Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)
This study is currently recruiting participants.
Verified April 2013 by Merck
Study NCT01295632
Information provided by Merck
First Received on February 9, 2011.
Last Updated on April 19, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
